DNIB0600A

DRUG3 trials

Sponsors

Genentech, Inc.

Conditions

Non-Small Cell Lung Cancer, Ovarian CancerNon-Squamous Non-Small Cell Lung CancerOvarian Cancer

Phase 1

Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer

CompletedNCT01363947

Genentech, Inc.Non-Small Cell Lung Cancer, Ovarian Cancer

Start: 2011-06-14End: 2016-06-03Updated: 2017-06-07

A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

CompletedNCT01995188

Genentech, Inc.Non-Squamous Non-Small Cell Lung Cancer

Start: 2013-12-16End: 2016-11-09Updated: 2017-10-04

Phase 2

A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)

TerminatedNCT01991210

Genentech, Inc.Ovarian Cancer

Start: 2014-02-06End: 2016-08-17Updated: 2017-08-21

Related Papers

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.

2018-04-0166 citations

A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC).

Journal of Clinical Oncology2016-05-206 citations